Maresins (alternative spelling for Maresins) are Specialized pro-resolving mediators (SPMs) derived from DHA through 12-LOX enzymatic conversion in macrophages. Named for "macrophage mediators in resolving inflammation," the maresin family includes MaR1, MaR2, and related molecules that actively orchestrate resolution rather than simply blocking inflammatory processes. They bind specific G protein-coupled receptors to promote Efferocytosis, reduce neutrophil trafficking, and enhance tissue regeneration.
Think of maresins as the cleanup crew that arrives after a factory fire. Most anti-inflammatory drugs are like turning off the fire alarm—they stop the noise but don't clean up the damage. Maresins are the specialized team that arrives with brooms, vacuums, and repair tools. They don't just suppress the emergency response; they actively coordinate the cleanup: directing workers (macrophages) to sweep up debris (apoptotic cells via Efferocytosis), telling fire trucks (neutrophils) to stop arriving, and calling in contractors to repair damaged walls (tissue regeneration). The factory manager (12-LOX) specifically hires this crew from the omega-3 supply warehouse (DHA). Without enough DHA in storage, you can't hire enough cleanup crews—the factory stays partially damaged, and chronic dysfunction sets in. The cleanup crew even has specialized equipment (receptors like LGR6) that only they can use, making them irreplaceable for proper recovery.
Maresin biosynthesis follows a precise enzymatic cascade initiated in M2 macrophages during the resolution phase of inflammation:
Biosynthetic Pathway:
- DHA (docosahexaenoic acid, 22:6n-3) is released from membrane phospholipids by Phospholipase A2
- 12-LOX (12-lipoxygenase) converts DHA → 14S-hydroperoxy-DHA (14S-HpDHA)
- 14S-HpDHA undergoes enzymatic epoxidation → 13S,14S-epoxy-maresin intermediate
- Hydrolysis yields MaR1 (7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid)
- Alternative 12-LOX processing generates MaR2 (13R,14S-dihydroxy-DHA)
Receptor Signaling:
- MaR1 binds LGR6 (leucine-rich repeat-containing G protein-coupled receptor 6) → Gαs/Gαi coupling
- Activates cAMP/PKA pathway → phosphorylates CREB → transcription of resolution genes
- Simultaneously inhibits NF-kB translocation → ↓ IL-6, TNF-α, IL-1β production
- Activates PI3K/AKT pathway → ↑ phagocytic capacity, cell survival signals
Cellular Actions:
graph TD
A[DHA from membrane] -->|PLA2| B[Free DHA]
B -->|12-LOX| C[14S-HpDHA]
C -->|Epoxidation| D[13S,14S-epoxy-maresin]
D -->|Hydrolysis| E[MaR1]
D -->|Alternative pathway| F[MaR2]
E -->|LGR6 receptor| G["Gαs/Gαi coupling"]
G --> H["↑ cAMP/PKA"]
G --> I["↓ NF-κB"]
G --> J["↑ PI3K/Akt"]
H --> K[CREB activation]
K --> L[Resolution gene transcription]
I --> M["↓ Pro-inflammatory cytokines"]
M --> N["↓ IL-6, TNF-α, IL-1β"]
J --> O[Enhanced efferocytosis]
J --> P["↑ Macrophage survival"]
E --> Q[TRPV1/TRPA1 inhibition]
Q --> R["↓ Pain signaling"]
Metabolic Inactivation:
- Maresins undergo oxidative inactivation by 15-LOX and COX-2 → formation of less active metabolites
- Dehydrogenation by prostaglandin dehydrogenase → complete inactivation
- Half-life in vivo: 15-30 minutes (ensuring temporal control of resolution)
Maresins represent a paradigm shift from anti-inflammation to pro-resolution therapeutics, directly relevant to chronic inflammatory conditions characterized by resolution deficit.
Clinical Applications:
- Chronic pain and Fibromyalgia: Maresin deficiency correlates with persistent pain states; low MaR1 levels (<0.5 pg/mL plasma) predict treatment resistance to NSAIDs
- Inflammatory bowel disease: MaR1 reduces intestinal inflammation (clinical trials show 40% symptom improvement with DHA 4g/d targeting maresin synthesis)
- Type 2 Diabetes and Metabolic syndrome: Maresins enhance insulin sensitivity by resolving adipose tissue inflammation; correlate with improved HbA1c (0.3-0.5% reduction)
- Acute Kidney Injury and Chronic Kidney Disease: MaR1 protects against ischemia-reperfusion injury and fibrosis progression
- Post-surgical recovery: Higher endogenous maresin production predicts faster wound healing and reduced chronic pain development
Evolutionary and Metamodel Context:
- Mismatch paradigm: Modern low Omega-3 intake (omega-6:omega-3 ratios >15:1 vs ancestral 2:1) creates chronic resolution deficit—the body can't manufacture enough cleanup crews
- Selfish Immune System: When maresins are scarce, the immune system remains in pro-inflammatory mode to ensure pathogen clearance, sacrificing tissue health (immune system "selfishly" protects itself at metabolic expense)
- Allostatic load: Repeated inflammatory episodes without adequate resolution deplete DHA stores and 12-LOX capacity → accumulating tissue damage
- Intermittent Living: Maresin synthesis peaks during post-exercise recovery and post-meal resolution phases—chronic stress and constant feeding disrupt temporal resolution windows
Intervention Implications:
- High-dose Omega-3 supplementation: 2-4g EPA+DHA daily (must be >50% DHA for maresin synthesis); verify omega-3 index >8%
- Enhance 12-LOX activity: Ensure adequate vitamin E (protects enzyme from oxidation), vitamin B6 (cofactor), zinc (structural stability)
- Timing matters: DHA supplementation with evening meals aligns with circadian resolution phase (peak 12-LOX expression 18:00-22:00)
- Avoid resolution inhibitors: Aspirin acetylates COX-2, creating aspirin-triggered lipoxins but competitively inhibiting maresin formation
- Support Efferocytosis: Combine with vitamin A (enhances phagocyte clearance), adequate protein (synthesis of phagocytic machinery)
Clinical Thresholds:
- Plasma MaR1 <0.3 pg/mL: severe resolution deficit (seen in active Crohn's disease, severe Rheumatoid Arthritis)
- Plasma MaR1 0.3-1.0 pg/mL: suboptimal resolution capacity (chronic low-grade inflammation)
- Plasma MaR1 >1.0 pg/mL: adequate resolution capacity (correlates with successful treatment responses)
- Target DHA:AA ratio >0.75 for optimal maresin synthesis substrate availability
- Derived from DHA via 12-LOX enzyme in M2 macrophages during resolution phase
- Named for "macrophage mediators in resing inflammation" (maresins)
- Includes MaR1 (most studied), MaR2, and 22-carbon epimeric series
- MaR1 binds LGR6 receptor (Leucine-rich repeat G protein-coupled receptor 6)
- Enhances Efferocytosis by 50-70% at nanomolar concentrations (IC50 ~10 nM)
- Reduces neutrophil infiltration without impairing pathogen clearance
- Promotes Macrophage Polarization from M1 → M2 phenotype
- Inhibits TRPV1/TRPA1 nociceptor channels → direct analgesic effect independent of inflammation
- Short half-life (15-30 minutes) ensures temporal resolution control
- Plasma levels <0.3 pg/mL indicate severe resolution deficit in chronic inflammatory disease
- Requires adequate tissue DHA stores (omega-3 index >8%) and functional 12-LOX enzyme
- Distinct from anti-inflammatory drugs: actively promotes resolution rather than blocking inflammation
- Maresins — primary spelling/synonym for this SPM family
- MaR1 — most extensively studied maresin family member with established LGR6 receptor binding
- MaR2 — second characterized maresin with distinct 13R,14S-dihydroxy configuration
- Specialized pro-resolving mediators (SPMs) — maresins constitute one of four major SPM families alongside Resolvins, Protectins, and Lipoxins
- DHA — essential biosynthetic precursor; maresin production directly proportional to tissue DHA availability
- 12-LOX — rate-limiting enzyme for maresin biosynthesis; requires B6, vitamin E, zinc cofactors
- 12,13-diHOME — related lipid mediator from linoleic acid via 12-LOX, shares similar resolution properties
- M2 macrophages — primary cellular source producing maresins during active resolution phase
- Efferocytosis — key cellular process enhanced 50-70% by MaR1 via phosphatidylserine receptor upregulation
- Resolution — biological endpoint actively promoted by maresins through multi-pathway coordination
- Neutrophil — cellular target; maresins reduce neutrophil recruitment without impairing antimicrobial function
- Omega-3 — dietary source category; low omega-3 intake creates maresin synthesis substrate deficit
- Inflammation — biological process that maresins resolve rather than suppress
- COX-2 — dual role: maresin metabolism enzyme and competitor for DHA substrate
- 15-LOX — metabolizes maresins to less active products, limiting resolution signal duration
- Lipoxins — related SPM family from Arachidonic acid; maresins complement lipoxin actions in resolution
- Resolvin D-series — related DHA-derived SPMs via 5-LOX; work synergistically with maresins
- TRPV1 — nociceptor channel directly inhibited by MaR1, providing pain relief independent of inflammation
- Chronic pain — clinical condition characterized by maresin deficiency and failed resolution
- Type 2 Diabetes — metabolic disease improved by maresins through adipose tissue inflammation resolution
- Inflammatory bowel disease — GI condition showing clinical improvement with DHA supplementation targeting maresin synthesis
- Macrophage Polarization — immunological process where maresins drive M1→M2 transition for tissue repair
- NF-kB — transcription factor inhibited by maresin signaling, reducing pro-inflammatory cytokine production
- CREB — transcription factor activated downstream of LGR6 receptor, driving resolution gene expression
- PI3K/AKT pathway — signaling cascade activated by MaR1 to enhance phagocytosis and cell survival